PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Cost reduction while AXSM shows 4.74% growth. Joel Greenblatt would examine competitive advantage.
100.00%
Gross profit growth exceeding 1.5x AXSM's 21.76%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
10.75%
R&D growth while AXSM reduces spending. John Neff would investigate strategic advantage.
-21.32%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.47%
Operating expenses growth 1.25-1.5x AXSM's 1.14%. Martin Whitman would scrutinize control.
1.47%
Total costs growth 1.1-1.25x AXSM's 1.32%. Bill Ackman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
6.88%
D&A growth above 1.5x AXSM's 3.41%. Michael Burry would check for excessive investment.
-1.39%
EBITDA decline while AXSM shows 22.40% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-1.47%
Operating income decline while AXSM shows 19.76% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-3.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-1.89%
Pre-tax income decline while AXSM shows 18.58% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.89%
Net income decline while AXSM shows 18.58% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
2.63%
EPS growth below 50% of AXSM's 19.76%. Michael Burry would check for structural issues.
2.63%
Diluted EPS growth below 50% of AXSM's 19.76%. Michael Burry would check for structural issues.
3.22%
Share count reduction below 50% of AXSM's 1.19%. Michael Burry would check for concerns.
3.22%
Diluted share reduction below 50% of AXSM's 1.19%. Michael Burry would check for concerns.